<DOC>
	<DOCNO>NCT02447432</DOCNO>
	<brief_summary>The primary aim study demonstrate investigational 4-dose presentation 10Pn-PD-DiT vaccine preservative non-inferior license presentation Synflorix ( preservative-free ) term immune response 10 vaccine pneumococcal serotypes ( primary objective ) vaccine-related pneumococcal serotype 19A ( first secondary objective ) , administration 3-dose primary vaccination course 6 , 10 18 week age co-administered first 2 dos DTPw-HBV/Hib vaccine give 6 , 10 14 week age ( accord Expanded Program Immunization ( EPI ) schedule ) . In addition , study also assess safety , reactogenicity , immunogenicity antibody persistence ( approximately 7 month follow primary vaccination ) 4-dose presentation 10Pn-PD-DiT vaccine give primary vaccination schedule 6 , 10 18 week age follow booster dose 38 week . This study also aim assess safety , reactogenicity immunogenicity 4-dose presentation 10Pn-PD-DiT vaccine give booster dose approximately 9 month age .</brief_summary>
	<brief_title>A Study Compare Immunogenicity GSK Biologicals ' 10Pn-PD-DiT 4-dose Presentation Licensed 1-dose Synflorix™ ( 10Pn-PD-DiT ) Vaccine When Co-administered With DTPw-combination Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects , opinion investigator , parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol ( e.g. , return vaccination followup visit ) . A male female , include 610 week ( 4276 day ) age time first vaccination . Written oral , sign thumbprinted informed consent obtain parent ( ) /LAR ( ) subject . For subject , consent form countersign witness . Healthy subject establish medical history clinical examination enter study . Born fullterm ( i.e. , gestation period 37 42 week ) . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug since birth . Inhaled topical steroid allow . Planned administration longacting immunemodifying drug time study period ( e.g. , infliximab ) . Administration plan administration vaccine foreseen study protocol administer period start 30 day dose study vaccine end 30 day follow exception : Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product Previous vaccination diphtheria , tetanus , pertussis , H. influenzae type b and/or S. pneumoniae . History , intercurrent diphtheria , tetanus , pertussis , hepatitis B , H. influenzae type b disease . History reaction hypersensitivity likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . History neurological disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C oral , axillary tympanic route , ≥ 38.0°C rectal route . The preferred route record temperature study axillary . Subjects minor illness without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product since birth plan administration study period ( Hepatitis B immunoglobulins birth allow ) . Any medical condition might interfere assessment study objective opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>76 Days</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Invasive disease Streptococcus pneumoniae ( S. pneumoniae ) ( include sepsis , meningitis , pneumonia , bacteraemia acute otitis medium )</keyword>
	<keyword>Infants</keyword>
	<keyword>Multidose</keyword>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Preservative</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal conjugate vaccine</keyword>
	<keyword>Acute otitis medium cause non-typeable Haemophilus influenzae ( NTHi ) .</keyword>
	<keyword>Respiratory tract infection</keyword>
</DOC>